Becton Dickinson and Co (BDX) : Catawba Capital Management Va scooped up 190 additional shares in Becton Dickinson and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 7, 2016. The investment management firm now holds a total of 44,282 shares of Becton Dickinson and Co which is valued at $7,855,627.Becton Dickinson and Co makes up approximately 1.89% of Catawba Capital Management Va’s portfolio.
Other Hedge Funds, Including , Exxonmobil Investment Management Inc Tx reduced its stake in BDX by selling 561 shares or 1.02% in the most recent quarter. The Hedge Fund company now holds 54,368 shares of BDX which is valued at $9,644,883. Becton Dickinson and Co makes up approx 0.20% of Exxonmobil Investment Management Inc Tx’s portfolio.Bnp Paribas Arbitrage Sa reduced its stake in BDX by selling 27,316 shares or 20.6% in the most recent quarter. The Hedge Fund company now holds 105,296 shares of BDX which is valued at $18,600,538. Becton Dickinson and Co makes up approx 0.08% of Bnp Paribas Arbitrage Sa’s portfolio.Burns J W Co Incny boosted its stake in BDX in the latest quarter, The investment management firm added 1,258 additional shares and now holds a total of 18,255 shares of Becton Dickinson and Co which is valued at $3,224,746. Becton Dickinson and Co makes up approx 1.00% of Burns J W Co Incny’s portfolio. Hefty Wealth Partners added BDX to its portfolio by purchasing 388 company shares during the most recent quarter which is valued at $68,540. Becton Dickinson and Co makes up approx 0.05% of Hefty Wealth Partners’s portfolio.Eqis Capital Management reduced its stake in BDX by selling 77 shares or 1.87% in the most recent quarter. The Hedge Fund company now holds 4,048 shares of BDX which is valued at $715,079. Becton Dickinson and Co makes up approx 0.04% of Eqis Capital Management’s portfolio.
Becton Dickinson and Co opened for trading at $177.39 and hit $177.81 on the upside on Friday, eventually ending the session at $177.4, with a gain of 0.16% or 0.29 points. The heightened volatility saw the trading volume jump to 6,17,071 shares. Company has a market cap of $37,773 M.
On the company’s financial health, Becton Dickinson and Co reported $2.35 EPS for the quarter, beating the analyst consensus estimate by $ 0.15 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $2.20. The company had revenue of $3198.00 million for the quarter, compared to analysts expectations of $3202.11 million. The company’s revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.05 EPS.
Many Wall Street Analysts have commented on Becton Dickinson and Co. Becton Dickinson and Co was Downgraded by Citigroup to ” Sell” on Sep 23, 2016.
Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.